FICPI WORLD CONGRESS
PHARMACEUTICAL PATENT ISSUES
“Incremental” patent rights and “Evergreening”

Patent rights covering innovations on a patented API, such as new dosages, new combinations, new forms (i.e. polymorphs or enantiomers) or new methods of use.

Concerns have been raised that this strategy might be used to prolong patent protection in an inappropriate manner, creating a negative effects on access to medicines as well as on further innovation.
Several countries, mainly developing and least developed countries (such as India, Brazil but also Australia), have changed or are considering changing their laws or practices in order to prevent "evergreening".

"Incremental" patent rights may nevertheless confer new and inventive clinical improvements and therapeutic advantages.

May thus deserve patent protection.
Speakers selected to provide the audience with different, if not opposite, points of view and stimulate a discussion.

Are the concerns raised with respect to “evergreening” justified?

Is it possible to protect both the interests of patent holders and public health?
Moderator:
Roberto Pintolesi (IT)
Partner & CEO
European Patent Attorney
Dragotti & Associati
PHARMACEUTICAL PATENT ISSUES

Speaker:
Jürgen Dressel PhD (DE)
Head Global Patent Litigation Strategy
Novartis Pharma AG
Speaker:
Fiona Bor PhD (UK)

Formerly at Teva and Mylan (VP and IP Director)
Speaker:
Ellen F.M. ‘t Hoen (NL)

Lawyer and Independent Consultant
Founder of Medicines Patent Pool
1999-2009 @ Médecins sans Frontières’
Speaker:
Louis Harms (Justice)

Former Deputy President of the Supreme Court of Appeal of SA; IP Professor @ University of Pretoria